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Background: Nonalcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of diseases, ranging from
simple steatosis to nonalcoholic steatohepatitis (NASH), which carries a significant risk of progression to cirrhosis
and hepatocellular carcinoma. Since NASH is a progressive but reversible condition, it is desirable to distinguish
NASH from simple steatosis, and to treat NASH patients at an early stage. To establish appropriate diagnosis and
therapy, the pathological mechanisms of the disease should be elucidated; however, these have not been fully
clarified for both NASH and simple steatosis. This study aims to reveal the differences between simple steatosis and
NASH.
Methods: This study used fatty liver Shionogi (FLS) mice as a NASH model, for comparison with dd Shionogi (DS)
mice as a model of simple steatosis. Genome-wide gene expression analysis was performed using Affymetrix
GeneChip Mouse Genome 430 2.0 Array, which contains 45101 probe sets for known and predicted genes.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry were used to
investigate gene expression changes and protein localizations.
Results: DNA microarray analysis of the liver transcriptomes and qRT-PCR of both types of mice revealed that LCN2,
CXCL1 and CXCL9 mRNAs were overexpressed in FLS mouse livers. Immunohistochemistry showed that CXCL1
protein was mainly localized to steatotic hepatocytes. CXCL9 protein-expressing hepatocytes and sinusoidal
endothelium were localized in some areas of inflammatory cell infiltration. Most interestingly, hepatocytes
expressing LCN2, a kind of adipokine, were localized around almost all inflammatory cell clusters. Furthermore,
there was a positive correlation between the number of LCN2-positive hepatocytes in the specimen and the
number of inflammatory foci.
Conclusions: Overexpression and distinct localization of LCN2, CXCL1 and CXCL9 in the liver of fatty liver Shionogi
mice suggest significant roles of these proteins in the pathogenesis of NASH.
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Table 1 Physiologic and biochemical parameters in FLS
and DS mice at 19 weeks of age
Variable FLS DS P value
Food intake (g/day) 4.0 ±0.1 4.1 ±0.1 NS
Body weight (g) 33.0 ±6.2 45.4 ±3.7 <0.001
Tissue weights
Liver (g) 1.65 ±0.44 1.85 ±0.33 NS
Liver (g)/BW(g) × 100 4.96 ±0.75 4.06 ±0.53 <0.01
Serum
AST (IU/L) 77 ±20 51 ±18 NS
ALT (IU/L) 84 ±50 23 ±3 <0.05
T-Cholesterol (mg/dL) 110 ±5 107 ±14 NS
Triacylglycerol (mg/dL) 103 ±42 85 ±32 NS
Abbreviations: AST aspartate aminotransferase, ALT alanine aminotransferase,
NS not significant.
Mean ± SD. (n = 3 to 9)
Mann–Whitney U-test for comparisons between groups.
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Nonalcoholic fatty liver disease (NAFLD) is the most
common etiology of chronic liver disease in the United
States and other developed countries [1]. It is closely as-
sociated with metabolic syndrome, which consists of a
constellation of insulin resistance, central obesity, hyper-
tension and dyslipidemia [2]. For this reason, NAFLD
has been regarded as a hepatic manifestation of meta-
bolic syndrome [3]. NAFLD includes a spectrum of liver
diseases ranging from simple hepatic steatosis (SS) to
nonalcoholic steatohepatitis (NASH) [4]; the latter is
known to increase the risk of liver cirrhosis and hepato-
cellular carcinoma [5]. Individuals with simple steatosis
rarely develop significant disease, whereas nearly 20% of
those with NASH progress to end-stages of liver disease
[6,7]. Evidence that cirrhosis and hepatocellular carci-
noma are more likely to develop in individuals with
NASH rather than those with SS suggests that NASH is
a more serious form of liver injury [6,8,9].
NASH is histologically similar to alcoholic steato-
hepatitis, with the presence of macrovesicular steatosis,
mixed inflammatory cell infiltration of the lobules, bal-
looning degeneration and necrosis of hepatocytes, Mallory
body formation, and perisinusoidal fibrosis [7]. Although
the pathogenesis of NASH remains unclear, hepatic
steatosis is the setting for NASH, with multiple ‘hits’ , such
as oxidative stress, inevitably leading to this progressive
form of inflammatory liver disease [9,10]. Furthermore,
the role of the gut microbiota and other new mechanisms
in the development of NAFLD have recently been disco-
vered [11]. An abnormality in the balance of secretion of
cytokines and adipokines is thought to be one such mul-
tiple ‘hit’ [10,12]. Therefore, investigation of cytokines/
adipokines has the potential to elucidate the pathogenesis
of NASH and to lead to the discovery of relevant bio-
markers. On the other hand, cytokines and adipokines are
also affected by inflammation and in simple obesity. Thus,
the pathological significance of the localization of these
molecules in NASH livers remains unclear. Further de-
tailed investigation is needed to develop cytokines and
adipokines as NASH markers. From an ethical perspective
[13], human liver biopsy cannot be performed casually be-
cause of its invasiveness, which has contributed to the
delay in clarification of the pathological details of NASH.
On the other hand, there are inbred experimental mice in
which the development of spontaneous fatty liver is a re-
sult of specific gene mutations, such as ob/ob, db/db, fat/
fat and tub/tub, although these animals do not develop
spontaneous NASH [14-17]. In recent years, the inbred
“fatty liver Shionogi” (FLS) mouse model has been deve-
loped [18]; these animals develop fatty livers in a setting of
insulin resistance under normal environmental conditions,
which finally progresses to concurrent hepatocellular car-
cinoma via steatohepatitis. These mice have been used asanimal models to compare the pathophysiology of NASH
with that of SS [18-22]. Therefore, in this study, as a first
step toward development of novel NASH biomarkers,
these mice and DS mice, which are a sister strain of FLS,




FLS and DS mice (9 each), aged 12 weeks, were
obtained from Aburabi Laboratories, Shionogi Research
Laboratories (Shionogi and Co., Ltd, Shiga, Japan).The
FLS mice were derived from the C line of an outbred
ddN colony [23] and were established as an inbred
strain by full-sib mating. The DS mice were derived
from the A line of an outbred ddN colony and were also
established as an inbred strain by full-sib mating [23].
The DS strain does not manifest liver abnormalities, in-
cluding NASH phenotype, [18] and was, thus, used as a
reference strain in this experiment. The mice, kept in
separate cages to prevent fighting, were housed in an
air-conditioned room at 23 ± 3°C and 50 ± 20% relative
humidity, with a 12 h light/12 h dark cycle (6:00–
18:00 hours). All mice were given a standard pellet diet
(CE-2; Clea Japan Inc, Tokyo, Japan), and free access to
water. The physiological and biochemical parameters of the
mice are summarized in Table 1. All experiments were car-
ried out in accordance with the Animal Experimentation
Guidelines of Chiba University and the study protocol was
approved by the Ethical Committee of Graduate School of
Medicine, Chiba University.
Sample collection
After administration of pentobarbital (Nembutal, Abbott
Laboratories, Chicago, IL, USA) for euthanizing the
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blood, and the livers were immediately removed, weighed
and sliced; one portion was fixed in a 15% neutral forma-
lin buffer solution, pH 7.4 (Wako Pure Chemicals, Tokyo,
Japan) and embedded in paraffin for histological analysis,
and the rest were snap frozen in liquid nitrogen and
stored at −80°C for subsequent analysis.
Light microscopy
Fixed tissues embedded in paraffin were sectioned and,
after appropriate standard treatments, were stained with
hematoxylin and eosin (H&E). The remaining formalin-
fixed liver tissues were processed for oil red O and
Masson’s Trichrome staining. Assessment of NAFLD
specimens was based on the criteria described by
Matteoni [7].
Microarray data analysis
Total RNA was extracted from the livers of 3 FLS and 3
DS mice at 19 weeks of age using RNeasy mini kits
(QIAGEN Inc., Valencia, CA, USA). RNA from each strain
was pooled and subjected to messenger RNA expression
profiling using a microarray (Mouse genome 430 2.0 array,
Affymetrix, Santa Clara, CA, USA). A copy of the full
microarray data set has been deposited in GEO Express
(accession no. GSE45624) and were normalized and
analyzed using the MBEI (PM-only) algorithm [24]. The
14 candidate NASH biomarkers (Table 2) having larger
expression differences between FLS livers and DS livers
were chosen according to criteria shown in Figure 1.
Among these candidates, we focused on genes encoding
immune response proteins (such as chemokines and






NM_011016 Orm2 orosomucoid 2
NM_011819 Gdf15 growth differentiation factor 15
AL385586 Ang angiogenin, ribonuclease, RNase A
X14607 Lcn2 lipocalin 2
NM_010406 Hc hemolytic complement
NM_008599 Cxcl9 chemokine (C-X-C motif) ligand 9
AW550625 Col3a1 collagen, type III, alpha 1
BB554288 Cxcl1 chemokine (C-X-C motif ) ligand 1
AKO11784 lgfbp2 insulin-like growth factor binding
BC005569 Rnase4 ribonuclease, RNase A family 4
BM122014 Gm6484 predcited gene 6484
BC025830 Pm20d1 peptidase M20 domain containing
NM_011315 Saa3 serum amyloid A 3
BF227507 Col1a2 collagen, type l, alpha 2cells differs markedly between NASH and SS, being min-
imal in SS and significantly up-regulated in NASH [25].
Quantitative real-time polymerase chain reaction
Total RNA was extracted from all mouse livers using an
RNeasy Mini kit and DNeasy Tissue kit (QIAGEN Inc.,
Valencia, CA, USA). cDNA was synthesized from total
RNA with the first-strand cDNA Synthesis kit for RT-
PCR (Roche, Mannheim, Germany). Quantitative (q)
PCR was carried out on the LightCycler 480 System
(Roche Diagnostics, Rotkreuz, Switzerland) using the
LightCycler 480 SYBR Green I Master (Roche Diagnos-
tics). The PCR primers used in this study are listed in
Table 3. Relative levels of mRNA in each sample were
expressed after normalization to β-actin as a housekee-
ping gene.
Immunohistochemistry
The primary antibodies used in this study are listed in
Table 4. Immunohistochemistry was performed on both
paraffin-embedded and frozen sections according to
standard protocols. The LSAB + system (DAKO Japan,
Kyoto, Japan) was used to visualize the tissue antigens
lipocalin-2 (LCN2), CXCL1 and CXCL9, according to the
manufacturer’s instructions. Histofine Simple Stain MAX-
PO (R) (Nichirei, Tokyo, Japan) and DAB solution (Dako)
were used to visualize CD3, F4/80 and the neutrophil
marker, according to the manufacturer’s instructions.
Morphometric analysis
The number of LCN2-positive hepatocytes and inflam-
matory foci (which included lymphocytes, macrophages













protein 2 2.5 12400.5 4979.9
2.4 7907.8 3254.3
2.4 1462.2 605.6
1 2.3 3390.0 1471.5
2.2 1242.3 553.2
2.0 632.6 315.6
Figure 1 Strategy for selection of potential serum biomarkers.
The potential serum biomarkers were searched for in the copy of
the full microarray data set has been deposited in GEO Express
(accession no. GSE45624). Biomarkers were selected on basis of
higher the gene expression ratio and potential secretion protein.
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expressed as mean cell count per 1 cm2 area of tissue.
Western blot analysis of LCN2
Protein extraction and western blotting were performed
as described previously [27] Anti-lipocalin-2 goat poly-
clonal antibody (R&D Systems, Inc., AF1857) diluted
1:250 and anti-β-actin goat polyclonal antibody (Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) diluted
1:500 in blocking buffer were used as primary antibodies.
Statistical analysis
Statistical analyses were performed using nonparametric
tests (R, version 2.13.2) [28]. Differences between the two
groups were evaluated by the Mann–Whitney U-test.
Associations between two parameters were evaluated by
Spearman rank correlation coefficients (Spearman’s ρ).
P values < .05 were considered significant.
Results
Histopathological observations
Large and small vacuoles were observed in H&E stained
liver specimens from both FLS and DS mice (Figure 2A,
B). Fat droplets in FLS livers were larger than those in DS
mice, and mild phagocytic infiltration of the liver lobules
was found in 8 FLS animals (89%), but in none (0%) of the
DS group animals (Figure 2C;a) (Table 5). Balloon-like
swelling of hepatocytes (a finding suggestive of hepatocyte
volume impairment due to excess fat accumulation) was
noted in 5 DS animals (56%) and in 8 FLS animals (89%)
(Figure 2C;b). Foamy appearance and eosinophilic necro-
sis were noted in FLS mice (Figure 2C;c, 2C;d, 3D). Mild
fibrosis of the liver was observed by Masson’s Trichrome
staining in several FLS mice (Figure 2C;e). Staining by Oil
red O confirmed accumulation of neutral fat in the
vacuoles (Figure 2C;f). Therefore, these experimental 19-
week-old FLS and DS mice were adopted as the NASH
and fatty liver models, respectively.
Varying degrees of inflammatory cell infiltration in
NASH mice
Clusters of hepatic inflammatory cells were identified in
the 19-week-old FLS mice by immunohistochemical
staining; neutrophil-marker-positive (Figure 3A), CD3-
positive (Figure 3B) and F4/80-positive (Figure 3C, D)





Table 4 Primary Antibodies used in this study
Antibody Catalog number Host Cell identified Source Tissue fixation Titre
Lcn2 AF1857 Goat - R&D Inc. * Formalin 1:50
Cxcl1 AF-453-NA Goat - R&D Formalin 1:100
Cxcl9 AF-492-NA Goat - R&D Formalin 1:100
Neutrophil Marker sc-59338 Rat Neutrophils Santa Inc. † Formalin 1:200
CD3 sc-101442 Rat Lymphocytes Santa Frozen 1:500
F4/80 sc-59171 Rat Macrophages Santa Formalin 1.50
*R&D Systems Inc., Minneapolis, Minnesota, USA. †Santa Cruz Biotechnology Inc., Santa Cruz, California, USA.
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or CD3 were found.
Identification of altered gene expression in NASH mice
As mentioned, we found marked fatty changes and in-
flammatory cell accumulations in FLS livers. We also
found that these inflammatory cells were heterogenous.
They mainly consisted of neutrophils and lymphocytes.
Therefore, we focused on inflammation-related mole-
cules, especially adipokines and chemokines, as possibleFigure 2 Microscopic findings in FLS and DS mouse livers at
19 weeks of age. (A) FLS mice, (B) DS mice, (C) Microscopic
characteristics of FLS mice at 19 weeks: (a) Focus of inflammation;
(b) Balloon cells; (c) Foamy cell (arrowhead); (d) Acidophilic body
(arrowhead); (e) Fibrosis (arrowheads); (f) Oil Red O staining. (A-C)
Hematoxylin and Eosin staining, original magnifications: A, B, ×100;
C-a, c, ×200; C-b, d, ×400. (C-e) Masson’s Trichrome staining; original
magnification, ×200. (C-f) Original magnification, ×60.NASH biomarker candidates. Messenger RNA expression
profiling revealed that adipokines (LCN2) and chemokines
(CXCL1, CXCL9) were among the genes upregulated in
FLS livers (Table 2).
Detection of LCN2 by qRT-PCR and
immunohistochemistry
Real-time PCR was used to determine the amounts of
LCN2 gene expression in the livers of 19-week-old mice;
expression was found to be increased significantly in
FLS compared to DS mice (0.118 ± 0.1015 vs. 0.01 ±
0.005, P = 0.00004) (Figure 4A). Western blot analysis
confirmed that LCN2 protein was increased in FLS as
compared to DS mice (Additional file 1: Figure S1).
Strongly positive immunohistochemical staining was ob-
served in parenchymal hepatic cell cytoplasm, especially
those in the vicinity of inflammatory cells (Figure 4D).
Furthermore, the number of LCN2-positive cells per
unit area, as determined by morphometric analysis, was
significantly greater in FLS as compared to DS mice
(P = 0.00028) (Figure 5A). Similarly, evaluation of the
number of foci of inflammatory cell clusters in serial
sections by H&E staining revealed that the number was
significantly greater in FLS as compared to DS mice
(P = 0.0004) (Figure 5B). There was a positive corre-
lation between the number of LCN2-positive hepatic
cells per unit area and the number of inflammatory cell
clusters in both groups of mice (Spearman’s ρ = 0.834;
P = 1.09E-05) (Figure 5C).
Detection of CXCL1 by qRT-PCR and
immunohistochemistry
Real-time PCR revealed that CXCL1 mRNA expression
was increased significantly in FLS as compared to DS mice
(0.041 ± 0.014 vs. 0.02 ± 0.001, P = 0.00078) (Figure 4B).
Furthermore, strongly positive CXCL1 staining was found
in steatotic hepatocytes; staining intensities tended to be
stronger in FLS as compared to DS mice (Figure 4E).
Detection of CXCL9 by qRT-PCR and
immunohistochemistry
The amount of CXCL9 mRNA expression was found to
be increased significantly in FLS as compared to DS







Normal(%) Fatty liver(%) Ballooning hepatocyto(%) Steatohepatitis(%)
FLS 19 9 0(0) 9(100) 8(89) 8(89)
DS 19 9 1(11) 8(89) 5(56) 0(0)
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(Figure 4C). Furthermore, strongly positive CXCL9 stai-
ning was found in the cytoplasm of hepatic parenchymal
cells in the vicinity of inflammatory cells, especially in the
sinusoidal endothelium, although some of these cells were
completely negative for CXCL9 (Figure 4F). This positive
reactivity was greater in FLS as compared to DS mice.
Discussion
NASH is a progressive disease; hence, discriminating
between benign fatty liver and NASH is very important
for prediction of its prognosis. Although establishment of
appropriate diagnosis and therapy requires elucidation of
the pathological mechanisms of this condition, these have
not been fully clarified for NASH and NAFLD.
NAFLD is a complex disease with no simple answers
[12]. However, epigenetic mechanisms of nuclear chro-
matin remodeling and oxidative stress, in particular, are
increasingly being recognized as crucial factors in the
pathophysiology of NAFLD [11]. Oxidative stress is asso-
ciated with the secretion of inflammatory biomolecules,
including cytokines. Indeed, during the chronic inflam-
mation present in NASH, a systemic release of pro-
inflammatory mediators from the liver occurs [11].
Therefore, it is likely that detailed study of the dynamicFigure 3 Immunohistochemistry of hepatic inflammatory focus in FLS
various immune cells. Immunostaining for (A) neutrophils, (B) lymphocytes
cells mainly consisted of neutrophils and lymphocytes.state of cytokine and adipokine levels in the NASH liver
may lead to deeper understanding of the disease, as well
as development of better disease markers.
The present study was a search for candidate NASH
markers through comprehensive gene expression analysis
of livers from NASH- and SS-model mice. Interestingly,
one adipokine (LCN2) and two chemokines (CXCL1,
CXCL9) were included in the top 14 genes identified as
candidate NASH markers (Table 2). Inflammatory cells
prominent in FLS mouse livers mainly consisted of neutro-
phils and lymphocytes (Figure 3). Therefore, we focused
on expression levels of lymphokines and chemokines in
this study. In terms of distribution in the hepatic lobule,
focal expressions of LCN2 were found in hepatic paren-
chymal cells in the vicinity of inflammatory cell clusters by
immunohistochemical staining techniques (Figure 4D),
and correlations were found between the number of in-
flammatory clusters and number of LCN2-positive cells in
the NAFLD (NASH and SS) mice (Figure 5C).
LCN2 was originally reported as a glycoprotein (NGAL)
with a molecular weight of 25 kDa that is present in leu-
kocytes [29]. Since then, it has been reported that it is
expressed in the liver upon administration of endotoxin
[30] and that it is produced in hepatic cell lines in re-
sponse to exposure to hydrogen peroxide [31]. In NASH,mice at 19 weeks of age. The inflammatory infiltration consisted of
, and (C, D) macrophages. Original magnification, ×400. Inflammatory
Figure 4 Confirmation of changes in the expression of several genes and representative findings of immunohistochemical staining in
FLS and DS mice livers at 19 weeks of age. Real-time PCR analysis of liver tissue from mice (n = 18) revealed altered gene expression for (A)
LCN2, (B) CXCL1, and (C) CXCL9, as detected by microarray analysis. Analysis results of the three genes were in directional concordance with
microarray results and were statistically significantly upregulated in FLS compared with DS mice (p < 0.05). Differences between the FLS and DS
groups were assessed by the Mann–Whitney U-test. (D) Hepatocytes strongly positive for LCN2 were aggregated close to most inflammatory foci,
whereas DS mice hepatocytes were scarcely stained. LCN2 protein was also expressed in some mononuclear cells in both types of mice
(arrowheads). (E) CXCL1 showed strong staining in some steatotic hepatocytes of FLS mice compared with faint staining in DS mice. (F) CXCL9
showed strong staining in the sinusoidal endothelium and hepatocytes present in the vicinity of some inflammatory cell clusters in FLS mice
(asterisks), whereas DS mice hepatocytes were scarcely stained.
Semba et al. BMC Gastroenterology 2013, 13:120 Page 7 of 11
http://www.biomedcentral.com/1471-230X/13/120the involvement of endotoxin, oxidative stress and cyto-
kines have been indicated as some of the multiple ‘hits’
[11,12]; this is compatible with the current findings of
LCN2 expression in NASH livers (Figure 4A, Additional
file 1 Figure S1). Furthermore, expression of LCN2 protein
was prominently observed in hepatic parenchymal cells in
the vicinity of inflammatory cells (Figure 4D). This sug-
gests that the hepatocytes in this microenvironment are
subjected to stresses, such as oxidative stress and exposureto cytokines. In recent years, it has been reported that
LCN2 plays a role in protecting hepatic cell lines from the
toxicity of hydrogen peroxide [32]. When combined with
the current results on the focal presence of LCN2 protein
in the NASH liver, it is possible that, in the pathogenesis
of NASH, liver LCN2 expression is increased in response
to cytotoxic stresses having origins in inflammatory cells.
On the other hand, there is a report indicating prominent
expression of LCN2 in the liver and visceral adipose
Figure 5 Quantification of LCN2 and inflammation in hepatic specimens from 19-week-old mice. (A) LCN2 protein expression: number of
positive hepatocytes per cm2; (B) Number of inflammatory foci per cm2; (C) Correlation between LCN2 protein-expressing hepatocytes (log scale)
and number of inflammatory foci (log scale) (n = 19). *Mann–Whitney U-test. ‡Spearman rank correlation coefficient; solid circles, DS; open
circles, FLS.
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due to excessive food intake, suggesting an association
between low-grade inflammation and diet-induced obesity
[33]. In another study as well, prominent expression of the
LCN2 protein was found in the visceral adipocytes of
obese patients (with insulin resistance and elevated high-
sensitivity CRP but without apparent liver injury) [34].
Thus, the results of the present study are consistent with
previous studies suggesting relationships between fatty
change, insulin resistance, inflammatory cell infiltration
and LCN2 expression in local tissues. However, further
basic or clinical studies are needed to test the pathogenic
or diagnostic values of LCN2 expression.
CXCL1 is known as a chemokine for neutrophils [35].
Forced expression of the CXCL1 gene in the rat liver was
accompanied by neutrophil infiltration, and led to hepatic
dysfunction (elevation of aspartate aminotransferase and
alanine aminotransferase) [36]. Furthermore, a correlation
was found between CXCL1 protein concentration andneutrophil count in the liver of patients with alcoholic
hepatitis [37]. In addition, neutrophilic infiltration of liver
tissue is known to cause insulin resistance in the liver
[38]. In the present study, CXCL1 protein was observed
mainly in the loci of steatotic hepatocytes, the staining
intensities of which tended to be stronger in FLS com-
pared to DS mice (Figure 4E), and a large number of infil-
trating neutrophils were observed in the liver of FLS mice
(Figure 3). To the best of our knowledge, this study is the
first to report the localization of CXCL1 protein in the
NASH liver; these results, considered together with those
of previous studies [35-38], suggest that CXCL1 is indeed
involved in the accumulation of hepatic neutrophils in this
disease and that neutrophilic infiltration may be involved
in insulin resistance in FLS livers [21,22].
While CXCL1 expression is elevated by the adminis-
tration of lipopolysaccharides in adipocytes co-cultured
with macrophages, this is not the case when lipopolysac-
charide is administered to adipocytes or macrophages
Figure 6 Hypothesis of the role of LCN2, CXCL1 and CXCL9 in the pathogenesis of NASH. Inflammatory chemokines, CXCL1 and CXCL9,
are produced in the NASH liver and lead to the recruitment of inflammatory cells, such as lymphocytes and neutrophils. Expression of the CXCL1
gene is known to be accompanied by neutrophil infiltration, and to lead to hepatic dysfunction [36]. CXCL9 is a molecule that is chemotactic for
lymphocytes [41]. The adipokine, LCN2, was observed in the cytoplasm of parenchymal hepatic cells, especially those in the vicinity of
inflammatory cells (Figure 4D). It has been reported that LCN2 plays a role in protecting cells from the toxic effects of oxidative stress [32].
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expression in the liver is elevated, and that the number of
myeloperoxidase-positive neutrophils is increased, by pro-
voking Fas-induced apoptosis in the livers of mice with
obesity induced by a high-fat diet [40]. We observed
macrophage clusters and eosinophilic necrotic cells in the
NASH mouse model used in the current study (Figure 2).
Furthermore, expression of CXCL1 was significantly higher
in the livers of NASH mice than SS mice (Figure 4B).
These results suggest the possibility that, in comparison to
SS livers, interactions between a number of hepatic factors
and fat deposits could be involved in the greater elevation
of CXCL1 expression in NASH livers; additional studies
are required to explore the mechanisms leading to hepatic
CXCL1 elevation in NASH.
CXCL9 is a chemokine with a molecular weight of
14 kDa that is chemotactic for Th1 (CD4 + T lympho-
cytes) and NK cells, and is mediated by the CXCR3 recep-
tor [41]. It has been reported that CXCL9 gene expression
is elevated after stimulation of mouse monocytes, neutro-
phils and hepatocytes by interleukin γ and viral infection
[42]. In the livers of HCV-infected mice, this protein was
found to be expressed in hepatic parenchymal cells in the
vicinities of sinuses and lymphocytes [43], and was also
related to the grade of hepatic fibrosis [43,44]. In addition,
it has been reported that in vitro experiments have
suggested the possibility that migration of CD4 +T lym-
phocytes to hepatic parenchyma in response to CXCL9
chemotaxis is mediated by biliary epithelial cells [45]. In the
current experiments, expression of this protein was found
in the hepatic parenchyma and sinusoids in the vicinity of
some of the inflammatory cell clusters in NASH livers
(Figure 4F), consistent with previous reports; to the best of
our knowledge, this is the first clear demonstration of the
localization of CXCL9 protein in the NASH liver. Additionally,in this study, CXCL9 gene expression in NASH mice was
greater than that in SS mice (Figure 4C). We also found CD3
positive pan-T cells in the NASH livers (Figure 3B). These re-
sults suggest the possibility that CXCL9 is involved in hepatic
inflammatory cell infiltrations in NASH.
Conclusions
In conclusion, as a result of comparative transcriptome
analysis of mice livers presenting with NASH and SS, we
found that the adipokine LCN2, and chemokines CXCL1
and CXCL9 are overexpressed in NASH livers. Immuno-
histochemical studies revealed that these genes are re-
lated to the inflammatory process of NASH. We have
schematically shown our hypothesis for their role in the
pathogenesis of NASH in Figure 6. We found a corre-
lation between hepatic LCN2 protein expression levels
and inflammatory foci, suggesting that LCN2 may be a
potential inflammatory marker of NASH.
Additional file
Additional file 1: Figure S1. Western blot confirmation that LCN2
protein is more strongly expressed in the tissues of FLS mice (n = 3) than
DS mice (n = 3).
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